tirzepatide head to head semaglutide SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Tirzepatide vs Semaglutide | Best
Pay in 4 interest-free payments of $5.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12




























:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)

